



Bacterial resistance modifying tetrasaccharide agents from *Ipomoea murucoides*

Lilia Chérigo^a, Rogelio Pereda-Miranda^{a,*}, Simon Gibbons^b

^a Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Mexico City 04510DF, Mexico

^b Centre for Pharmacognosy and Phytotherapy, The School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX, UK

ARTICLE INFO

Article history:

Received 15 September 2008

Received in revised form 9 November 2008

Available online 10 January 2009

Keywords:

Ipomoea murucoides
Convolvulaceae
Staphylococcus aureus
Structural spectroscopy
Multidrug resistance
Resin glycoside
Tetrasaccharide
NMR

ABSTRACT

As part of an ongoing project to identify oligosaccharides which modulate bacterial multidrug resistance, the CHCl₃-soluble extract from flowers of a Mexican arborescent morning glory, *Ipomoea murucoides*, through preparative-scale recycling HPLC, yielded five lipophilic tetrasaccharide inhibitors of *Staphylococcus aureus* multidrug efflux pumps, murucoidins XII–XVI (1–5). The macrocyclic lactone-type structures for these linear hetero-tetraglycoside derivatives of jalapinic acid were established by spectroscopic methods. These compounds were tested for in vitro antibacterial and resistance modifying activity against strains of *Staphylococcus aureus* possessing multidrug resistance efflux mechanisms. Only murucoidin XIV (3) displayed antimicrobial activity against SA-1199B (MIC 32 µg/ml), a norfloxacin-resistant strain that over-expresses the NorA MDR efflux pump. The four microbiologically inactive (MIC > 512 µg/ml) tetrasaccharides increased norfloxacin susceptibility of this strain by 4-fold (8 µg/ml from 32 µg/ml) at concentrations of 25 µg/ml, while murucoidin XIV (3) exerted the same potentiation effect at a concentration of 5 µg/ml.

© 2008 Elsevier Ltd. All rights reserved.

1. Introduction

All Mexican medicinal arborescent members of the genus *Ipomoea* (Convolvulaceae) share two therapeutic properties: the raw flowers, used antiseptically, are rubbed directly on skin infections, itching and rashes, and as decoctions, plasters and poultices, and in some instances the leaves, stem and bark are used for rheumatism, inflammation, and muscular pain (Chérigo and Pereda-Miranda, 2006). “Cazahuatl”, Nahuatl (Aztec language) for “tree to cure mange”, is the vernacular name in contemporary Mexican Spanish for this group of arborescent species belonging to the genus *Ipomoea* series Arborescentes, e.g., *Ipomoea murucoides* Roem. et Schult. In the 16th century account of Mexican pre-Hispanic herbolaria “De la Cruz-Badiano Codex” (Emmart, 1940), the antiseptic properties for this medicinal plant complex are confirmed in a description of how Aztec healers used this herbal drug to prevent hair loss.

Murucoidins, a series of related lipophilic pentasaccharides of jalapinic acid, were first reported in the chemical analysis of resin glycosides from this crude drug (Chérigo and Pereda-Miranda, 2006). A second investigation followed for the identification of new resin glycoside inhibitors of bacterial growth and in some instances inhibitors of multidrug efflux to treat infections resulting from multidrug-resistant *S. aureus* strains. All tested murucoidins exerted a potentiation effect of norfloxacin against the NorA over-expressing strain SA-1199B by increasing the activity 4-fold

(8 µg/ml from 32 µg/ml) at concentrations of 5–25 µg/ml (Chérigo et al., 2008). This work was undertaken to increase the recognition of chemical diversity of the target oligosaccharides which modulate bacterial multidrug resistance, basically by isolating compounds from a new plant collection of *I. murucoides* that displayed variations in its resin glycoside composition.

2. Results and discussions

CHCl₃-soluble extracts of a new collection of the crude drug “Cazahuatl” were compared by C₁₈ reversed-phase HPLC with reference solutions of the previously reported resin glycosides from this species (Chérigo et al., 2008). This analysis confirmed a higher complexity in their composition and allowed the detection of the known pentasaccharides stoloniferin I, pescaprein III, intrapilosin I, and murucoidins I–V, as well as five new constituents, murucoidins XII–XVI (1–5) which were separated and purified by using a recycling HPLC technique (Pereda-Miranda and Hernández-Carlos, 2002). Several NMR techniques and FABMS were used to characterize their structures which were found to be macrolactones of the known operculinic acids C and E, linear hetero-tetraglycosides of jalapinic acid, with *n*-dodecanoic or (2S)-methylbutyric acids esterifying the C-2 or C-3 positions on the second rhamnose unit of the oligosaccharide core and (2S)-methylbutyric acid at C-4 on the third rhamnose moiety.

A small portion of the glycosidic mixture was saponified to liberate an H₂O-soluble mixture of five oligosaccharides of jalapinic acid: the major products were identified as operculinic acid A and

* Corresponding author. Tel.: +52 55 5622 5288; fax: +52 55 5622 5329.
E-mail addresses: pereda@unam.mx, pereda@prodigy.net.mx (R. Pereda-Miranda).

simonic acids A and B by HPLC retention time comparison with those of authentic samples (Chérigo et al., 2008). Two additional glycosidic acids represented minor constituents and were characterized as operculinic acid C: (11S)-hydroxyhexadecanoate 11-O- α -L-rhamnopyranosyl-(1 \rightarrow 4)-O- α -L-rhamnopyranosyl-(1 \rightarrow 4)-O- α -L-rhamnopyranosyl-(1 \rightarrow 2)- β -D-fucopyranoside, and operculinic acid E: (11S)-hydroxyhexadecanoate 11-O- α -L-rhamnopyranosyl-(1 \rightarrow 4)-O- α -L-rhamnopyranosyl-(1 \rightarrow 4)-O- α -L-rhamnopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside, both previously isolated from *I. operculata* (Ono et al., 1989). Evidence for the absolute stereochemistry of the sugars, the configuration of the anomeric linkages as well as the sequence of glycosidation was published when their oligosaccharide cores were first elucidated (Ono et al., 1989, 1990). Sugar analysis confirmed that all monosaccharides were in their naturally occurring form as previously described (Chérigo et al., 2008).

Negative-ion FAB mass spectra generated by murucoidins XII and XIII (1–2) were found to be very similar, with a pseudomolecular $[M-H]^-$ ion at m/z 1119, and therefore these constituents rep-

resented diastereoisomeric tetrasaccharides of molecular formula $C_{57}H_{100}O_{21}$. Compounds 3 afforded a FAB mass spectrum with the $[M-H]^-$ ion at m/z 1103 ($C_{57}H_{99}O_{20}$). Careful analysis of the negative FABMS generated by these tetrasaccharides 1–3 confirmed the nature of the oligosaccharide core for each glycolipid. The observed difference of 16 mass units in all diagnostic fragments for 3 in relation with 1 and 2 indicated the presence of a 6-deoxy-hexose (fucose) instead of the hexose unit (glucose). The initial loss of the dodecanoyl group afforded a peak at m/z 937 in 1 and 2 representing $[M-H-C_{12}H_{22}O]^-$, while the same elimination in 3 afforded the peak at m/z 921. The subsequent elimination of the methylbutyryl unit (84 mass units) in 1 and 2 afforded a peak at m/z 853 $[937-C_5H_8O]^-$, and the peak m/z 837 in 3. The ions produced by the rupture of each of the glycosidic linkages afforded the series of peaks at m/z 707, 561, 433 and 271 in 1 and 2 and at m/z 691 $[1067-2 \times 146 (C_6H_{10}O_4)-C_5H_8O]^-$, 545 $[691-146 (C_6H_{10}O_4)]^-$, which indicated that the lactonization was located at the first rhamnose unit (Rha), 417 $[545 + H_2O - 146 (C_6H_{10}O_4)]^-$, and 271

Table 1

1H (500 MHz) NMR spectroscopic data of compounds 1–5 (pyridine- d_5).^a

Proton ^b	1	2	3	4	5
glc-1	4.99 <i>d</i> (8.0)	5.00 <i>d</i> (8.0)			
2	4.30* <i>dd</i> (8.0, 8.0)	4.30* <i>dd</i> (8.0, 8.0)			
3	4.30 <i>dd</i> (8.0, 8.0)	4.30 <i>dd</i> (8.0, 8.0)			
4	4.17 <i>dd</i> (9.0, 9.0)	4.16 <i>dd</i> (9.0, 9.0)			
5	3.90*	3.90 <i>ddd</i> (2.0, 5.5, 9.0)			
6a	4.38 <i>dd</i> (5.6, 12.0)	4.40 <i>m</i>			
6b	4.52 <i>dd</i> (2.8, 12.0)	4.52 <i>dd</i> (3.0, 11.7)			
fuc-1			4.79 <i>d</i> (7.5)	4.69 <i>d</i> (7.5)	4.73 <i>d</i> (7.5)
2			4.54 <i>dd</i> (7.5, 9.5)	4.14 <i>dd</i> (7.5, 9.5)	4.14 <i>dd</i> (7.5, 9.5)
3			4.19 <i>dd</i> (3.0, 9.5)	4.00 <i>dd</i> (3.0, 9.5)	4.07 <i>dd</i> (3.0, 9.5)
4			3.92*	3.97 <i>m</i>	3.97 <i>brs</i>
5			3.82 <i>dq</i> (1.0, 6.5)	3.72 <i>dq</i> (1.0, 6.5)	3.77 <i>dq</i> (1.0, 6.5)
6			1.52 <i>d</i> (6.5)	1.50 <i>d</i> (6.5)	1.50 <i>d</i> (6.5)
rha-1	6.49 <i>d</i> (1.0)	6.51 <i>d</i> (1.5)	6.39 <i>d</i> (2.0)	5.49 <i>d</i> (2.0)	5.47 <i>d</i> (2.0)
2	5.28 <i>dd</i> (1.0, 3.0)	5.25 <i>dd</i> (1.5, 3.0)	5.25 <i>dd</i> (2.0, 3.0)	5.92 <i>dd</i> (2.0, 3.5)	5.90 <i>dd</i> (2.0, 3.5)
3	5.59 <i>dd</i> (3.0, 9.5)	5.69 <i>dd</i> (3.0, 9.5)	5.66 <i>dd</i> (2.5, 9.5)	4.99 <i>dd</i> (3.5, 9.5)	5.00 <i>dd</i> (3.5, 9.5)
4	4.63 <i>t</i> (9.5)	4.76 <i>t</i> (9.5, 9.5)	4.71 <i>t</i> (9.5)	4.20 <i>t</i> (9.5)	4.22 <i>t</i> (9.5)
5	5.08 <i>dq</i> (6.5, 9.5)	5.16 <i>dq</i> (6.5, 9.5)	5.08 <i>dq</i> (6.0, 9.5)	4.45 <i>dq</i> (6.5, 9.5)	4.45 <i>dq</i> (9.5, 6.5)
6	1.75 <i>d</i> (6.5)	1.75 <i>d</i> (6.5)	1.59 <i>d</i> (6.0)	1.64 <i>d</i> (6.5)	1.63 <i>d</i> (6.5)
rha'-1	5.57 <i>d</i> (1.5)	5.91 <i>d</i> (1.5)	5.89 <i>d</i> (1.5)	6.01 <i>d</i> (2.0)	6.16 <i>d</i> (2.0)
2	5.78 <i>dd</i> (1.5, 3.5)	4.71 <i>dd</i> (1.5, 3.0)	4.70 <i>dd</i> (1.5, 3.0)	5.95 <i>dd</i> (2.0, 3.5)	4.87 <i>dd</i> (2.0, 3.0)
3	4.59 <i>dd</i> (3.5, 9.5)	5.72 <i>dd</i> (3.0, 9.5)	5.71 <i>dd</i> (3.0, 9.5)	4.66 <i>dd</i> (3.5, 9.5)	5.74 <i>dd</i> (3.0, 9.5)
4	4.26 <i>t</i> (9.5, 9.5)	4.57 <i>t</i> (9.5, 9.5)	4.56 <i>t</i> (9.5, 9.5)	4.24 <i>t</i> (9.5, 9.5)	4.58 <i>t</i> (9.5, 9.5)
5	4.37 <i>dq</i> (6.0, 9.5)	4.43 <i>dq</i> (6.5, 9.5)	4.40 <i>dq</i> (6.0, 9.5)	4.38 <i>dq</i> (6.5, 9.5)	4.42 <i>dq</i> (6.5, 9.5)
6	1.69 <i>d</i> (6.0)	1.61 <i>d</i> (6.5)	1.58 <i>d</i> (6.0)	1.71 <i>d</i> (6.5)	1.65 <i>d</i> (6.5)
rha''-1	6.16 <i>d</i> (1.5)	5.68 <i>d</i> (1.5)	5.68 <i>d</i> (1.5)	6.13 <i>d</i> (1.5)	5.75 <i>d</i> (1.5)
2	4.77 <i>dd</i> (1.5, 3.0)	4.47 <i>dd</i> (1.5, 3.0)	4.46 <i>dd</i> (1.5, 3.5)	4.81 <i>brs</i>	4.53 <i>brs</i>
3	4.48 <i>dd</i> (3.0, 9.5)	4.40 <i>m</i>	4.38 <i>dd</i> (3.5, 9.5)	4.55 <i>dd</i> (3.0, 9.5)	4.47 <i>dd</i> (3.0, 9.5)
4	5.80 <i>t</i> (9.5)	5.76 <i>t</i> (9.5)	5.75 <i>t</i> (9.5, 9.5)	5.83 <i>t</i> (9.5, 9.5)	5.79 <i>t</i> (9.5, 9.5)
5	4.41 <i>dq</i> (6.0, 9.5)	4.32 <i>dq</i> (6.5, 9.5)	4.30 <i>dq</i> (6.0, 9.5)	4.43 <i>dq</i> (6.5, 9.5)	4.34 <i>dq</i> (6.5, 9.5)
6	1.44 <i>d</i> (6.0)	1.36 <i>d</i> (6.5)	1.35 <i>d</i> (6.0)	1.44 <i>d</i> (6.5)	1.35 <i>d</i> (6.5)
jla-2a	2.24 <i>ddd</i> (3.0, 8.0, 11.7)	2.13 <i>ddd</i> (3.7, 7.8, 11.5)	2.14 <i>ddd</i> (3.5, 7.0, 12.0)	2.22 <i>ddd</i> (3.5, 7.0, 12.0)	2.21 <i>ddd</i> (3.7, 8.0, 11.5)
2b	2.72 <i>ddd</i> (3.0, 8.0, 11.7)	2.25 <i>ddd</i> (3.7, 7.8, 11.5)	2.23 <i>ddd</i> (3.5, 7.0, 12.0)	2.44 <i>ddd</i> (3.5, 7.0, 12.0)	2.35 <i>ddd</i> (3.7, 8.0, 11.5)
11	3.90	3.96 <i>m</i>	3.92	3.84 <i>m</i>	3.85 <i>m</i>
16	1.00 <i>t</i> (7.0)	0.99 <i>t</i> (7.0)	0.99 <i>t</i> (7.0)	0.88 <i>t</i> (7.0)	0.88 <i>t</i> (7.5)
mba-2	2.52 <i>tq</i> (7.0, 7.0)	2.48 <i>tq</i> (7.0, 7.0)	2.47 <i>tq</i> (7.0, 7.0)	2.40 <i>tq</i> (7.0, 7.0)	2.45* <i>tq</i> (7.0, 7.0)
2-Me	1.22 <i>d</i> (7.0)	1.20 <i>d</i> (7.0)	1.20 <i>d</i> (7.0)	1.21 <i>d</i> (7.0)	1.19 <i>d</i> (7.0)
3-Me	0.95 <i>t</i> (7.5)	0.92 <i>t</i> (7.5)	0.92 <i>t</i> (7.5)	0.94 <i>t</i> (7.5)	0.91 <i>t</i> (7.5)
mba'-2				2.51 <i>tq</i> (7.0, 7.0)	2.45 <i>tq</i> (7.0, 7.0)
2-Me				1.08 <i>d</i> (7.0)	1.13 <i>d</i> (7.0)
3-Me				0.85 <i>t</i> (7.5)	0.86 <i>t</i> (7.5)
dodeca-2a	2.27 <i>ddd</i> (7.5, 7.5, 15.0)	2.30 <i>ddd</i> (7.5, 7.5, 15.0)	2.27 <i>ddd</i> (7.0, 7.0, 15.0)		
2b	2.35 <i>ddd</i> (7.5, 7.5, 15.0)	2.39 <i>ddd</i> (7.5, 7.5, 15.0)	2.38 <i>ddd</i> (7.0, 7.0, 15.0)		
12	0.87 <i>t</i> (7.5)	0.87 <i>t</i> (7.0)	0.88 <i>t</i> (7.5)		

^a Chemical shifts (δ) are in ppm relative to TMS. The spin coupling (J) is given in parentheses (Hz). Chemical shifts marked with an asterisk (*) indicate overlapped signals. Spin-coupled patterns are designated as follows: *s* = singlet, *d* = doublet, *t* = triplet, *q* = quartet, *m* = multiplet, *brs* = broad singlet.

^b Abbreviations: fuc = fucose; rha = rhamnose; glc = glucose, jla = 11-hydroxyhexadecanoyl; mba = methylbutanoyl, dodeca = dodecanoyl.

[illegible]

	R ₁	R ₂	R ₃	R ₄	R ₅
1	H	<i>n</i> -dodecanoyl	OH	H	CH ₂ OH
2	<i>n</i> -dodecanoyl	H	OH	H	CH ₂ OH
3	<i>n</i> -dodecanoyl	H	H	OH	CH ₃

The image shows a complex chemical structure of a glycoside. It consists of a central glucose molecule in a chair conformation, linked via an ester bond to a side chain containing a chiral center (a carbon with a methyl group and a hydrogen atom). The glucose is also linked via an ether bond to another glucose molecule, which is further linked via an ester bond to a long-chain fatty acid derivative. The structure is labeled with R_1O and OR_2 groups.

	R ₁	R ₂
4	H	(2 <i>S</i>)-methylbutanoyl
5	(2 <i>S</i>)-methylbutanoyl	H

^b Abbreviations: fuc = fucose; rha = rhamnose; glc = glucose, jal = 11-hydroxy-hexadecanoyl; mba = methylbutanoyl; dodeca = dodecanoyl.

Table 3Susceptibility of *Staphylococcus aureus* to murucoidins XII–XVI (1–5) and their cytotoxicity.^a

Compound	ED ₅₀ (μg/ml)			MIC (μg/ml)				
	KB	Hep-2	HeLa	ATCC 25923	XU-212	EMRSA-15	SA-1199B ^b Nor (–)	Nor (+)
1	17.1	>20	>20	>512	>512	>512	512	8
2	>20	>20	>20	>512	>512	>512	512	8
3	13.6	3.6	16.0	>512	>512	>512	32	8 ^c
4	19.0	16.4	15.5	>512	>512	>512	512	8
5	14.1	>20	15.9	>512	>512	>512	512	8
Tetracycline	–	–	–	0.125	64	0.125	0.025	–
Norfloxacin	–	–	–	0.5	8	0.25	–	32
Reserpine	–	–	–	–	–	–	–	8 ^d
Vinblastine	0.003	0.007	0.008	–	–	–	–	–

^a Abbreviations: KB = nasopharyngeal carcinoma; Hep-2 = laryngeal carcinoma; HeLa = cervix carcinoma; ATCC 25923 = standard *S. aureus* strain; EMRSA-15 = epidemic methicillin-resistant *S. aureus* strain containing the *mecA* gene; XU-212 = a methicillin-resistant *S. aureus* strain possessing the TetK tetracycline efflux protein; SA-1199B = multidrug-resistant *S. aureus* strain over-expressing the NorA efflux pump.

^b Nor (–) = minimum inhibitory concentration (MIC) value determined in the susceptibility testing; Nor (+) = MIC value determined for norfloxacin in the modulation assay at the concentration of 25 μg/ml of the tested oligosaccharide.

^c MIC value for norfloxacin in the modulation assay at the concentration of 5 μg/ml of the tested oligosaccharide.

^d MIC value for norfloxacin in the modulation assay at the concentration of 20 μg/ml of reserpine which was used as positive control for an efflux pump inhibitor.

Only murucoidins XIV (3) displayed antimicrobial activity at the concentration tested against SA-1199B (MIC 8 μg/ml), a *Staphylococcus aureus* strain that over-expresses the NorA MDR efflux pump. All of the murucoidins strongly potentiated the action of norfloxacin against this NorA over-expressing strain (Gibbons et al., 2003; Oluwatuji et al., 2004) in experiments using a sub-inhibitory concentration of these oligosaccharides (Table 3). Compounds 1–5 exerted a potentiation effect which increased the activity of norfloxacin by 4-fold (8 μg/ml; from 32 μg/ml) at concentrations of 5–25 μg/ml. These increments in norfloxacin susceptibility were similar to those observed for the orizabins, tetrasaccharides from the resin glycoside mixture of Mexican scammony (*Ipomoea orizabensis*), and the lipophilic pentasaccharides previously isolated from *I. murucoides* (Chérigo et al., 2008; Pereda-Miranda et al., 2006). These compounds are amphiphilic with very similar logP values and they could cause non-specific membrane disruption, however if this was the case, all of these molecules would be active and the norfloxacin modulating activity could not be observed.

3. Concluding remarks

This is the first report of the presence of tetraglycosidic lactones of jalapinic acid in a tree-like morning glory species since the section *Arborescentes* is characterized by the presence of pentasaccharides (Chérigo and Pereda-Miranda, 2006; Bah et al., 2007). The observed variation in the resin glycoside composition of *I. murucoides* flowers seems to depend on the geographical distribution of this species and deserves further studies.

The potential use as therapeutic agents of this class of bacterial resistance modifiers for new efflux pump inhibitors is under investigation in view of the fact that by combining these plant non-cytotoxic products with commercial antibiotics could facilitate the reintroduction of ineffective antibiotics into clinical use for the treatment of refractive infections caused by multidrug-resistant *S. aureus* strains.

4. Experimental

4.1. General experimental procedures

All melting points were determined on a Fisher–Johns apparatus and are uncorrected. Optical rotations were measured with a Perkin–Elmer model 241 polarimeter. ¹H (500 MHz) and ¹³C (125.7 MHz) NMR experiments were conducted on a Bruker

DMX-500 instrument. The NMR techniques were performed in accordance with previously described methodology (Bah and Pereda-Miranda, 1996). Negative-ion low and high-resolution FAB–MS were recorded using a matrix of triethanolamine on a JEOL SX-102A spectrometer. The instrumentation used for HPLC analysis consisted of a Waters (Millipore Corp., Waters Chromatography Division, Milford, MA) 600 E multisolvent delivery system equipped with a refractive index detector (Waters 410).

4.2. Plant material

Flowers of *I. murucoides* were collected at Tepostlán, Morelos, Mexico, on April 15, 2001. The plant material was identified by Dr. Robert Bye and one of the authors (R.P.-M.) through comparison with an authentic plant sample (RP-05) archived at the Departamento de Farmacia, Facultad de Química, UNAM (Chérigo y Pereda-Miranda, 2006). A voucher specimen (Robert Bye 35906) was deposited in the Ethnobotanical Collection of the National Herbarium (MEXUE), Instituto de Biología, UNAM.

4.3. Extraction and isolation of compounds 1–5

The whole plant material (500 g) was powdered and extracted exhaustively by maceration at room temperature with CHCl₃ to afford, after removal of the solvent, a dark brown syrup (35.8 g). The crude extract was subjected to column chromatography over silica gel (500 g) using gradients of CH₂Cl₂ in hexane (1:1 and 1:0), Me₂CO in CH₂Cl₂ (1:9 and 3:7), and MeOH in Me₂CO–CH₂Cl₂ (0.5:2.5:7, 1:2:7, 2:1:7). A total of 250 fractions (200 ml each) were collected, examined by TLC and combined in eight fractions. Fraction IV (eluates 122–126; MeOH–Me₂CO–CH₂Cl₂, 1:2:7) and fraction V (eluates 127–132; MeOH–Me₂CO–CH₂Cl₂, 2:1:7) were combined to give a pool containing a mixture of resin glycosides (18 g) which was subjected to fractionation by open column chromatography over reversed-phase C₁₈ (150 g) eluted with MeOH. This process provided 40 secondary fractions (25 ml each). The subfraction 14–18 yielded a mixture of lipophilic resin glycosides (9.6 g) which were analyzed by reversed-phase HPLC using an isocratic elution with CH₃CN–MeOH (9:1). For their resolution, a Waters Symmetry C₁₈ column (300 × 19 mm), a flow rate of 9 ml/min, and a refractive index detector were used. Peaks with *t*_R values of 7.0 (28 mg, peak I), 7.8 (18.6 mg, peak II), 12.6 min (26 mg, peak III), 13.4 (16.5 mg, peak IV), 14.0 min (25.8 mg, peak V), 16.5 (18 mg, peak VI), 19.5 min (20 mg, peak VII), 22.0

(21.3 mg, peak VIII), 23.0 min (29 mg, peak IX), 24.9 (35.6 mg, peak X), and 30.5 (60 mg, peak XI) were collected by the technique of heart cutting and independently re-injected in the apparatus operating in the recycle mode to achieve total homogeneity after 15 consecutive cycles. An isocratic elution with CH₃CN–MeOH (7:3) was used for those peak with t_R values higher to 15 min. These techniques afforded pure murucoidin XIII (**2**, 15 mg) from peak III, murucoidin XII (**1**, 14 mg) from peak V, murucoidin XIV (**3**, 6 mg) from peak VII, and murucoidin XVI (**5**, 12 mg) from peak IX. Peak XI afforded murucoidin IV (28 mg) and murucoidin XV (**4**, 16 mg). Co-elution experiments with reference solutions of previously reported resin glycosides allowed the detection of the following compounds: murucoidin V from peak I (13.5 mg), stoloniferin I (10.2 mg) from peak II, murucoidin I (8.4 mg) from peak IV, pescaprein III (7.3 mg) from peak VI, murucoidin II (9.1 mg) from peak VIII, and murucoidin III (15 mg) from peak X. All known compounds were identified by comparison of NMR data with published values (Bah et al., 2007; Chérigo y Pereda-Miranda, 2006; Pereda-Miranda et al., 2005).

4.4. Compound characterization

4.4.1. Murucoidin XII (1)

White powder; mp 100–104 °C; $[\alpha]_D -78^\circ$ (c 0.2, MeOH); ¹H and ¹³C NMR, see Tables 1 and 2; negative FABMS m/z 1119 [M–H][–], 937 [M–H–C₁₂H₂₂O][–], 853 [937–C₅H₈O][–], 707 [853–C₆H₁₀O₄][–], 561, 433, 271; HRFABMS m/z 1119.6676 [M–H][–] (calcd for C₅₇H₉₉O₂₁ requires 1119.6679).

4.4.2. Murucoidin XIII (2)

White powder; mp 96–98 °C; $[\alpha]_D -67^\circ$ (c 0.1, MeOH); ¹H and ¹³C NMR, see Tables 1 and 2; negative FABMS m/z 1119 [M–H][–], 937 [M–H–C₁₂H₂₂O][–], 853 [937–C₅H₈O][–], 707 [853–C₆H₁₀O₄][–], 561 [707–C₆H₁₀O₄][–], 433 [561–128][–], 271; HRFABMS m/z 1119.6674 [M–H][–] (calcd for C₅₇H₉₉O₂₁ requires 1119.6679).

4.4.3. Murucoidin XIV (3)

White powder; mp 125–127 °C; $[\alpha]_D -60^\circ$ (c 0.47, MeOH); ¹H and ¹³C NMR, see Tables 1 and 2; negative FABMS m/z 1103 [M–H][–], 921 [M–H–C₁₂H₂₂O][–], 837 [921–C₅H₈O][–], 691 [837–C₆H₁₀O₄][–], 545 [691–C₆H₁₀O₄][–], 417, 271; HRFABMS m/z 1103.6724 [M–H][–] (calcd for C₅₇H₉₉O₂₀ requires 1103.6729).

4.4.4. Murucoidin XV (4)

White powder; mp 108–111 °C; $[\alpha]_D -66^\circ$ (c 0.60, MeOH); ¹H and ¹³C NMR, see Tables 1 and 2; negative FABMS m/z 1005 [M–H][–], 921 [M–H–C₅H₈O][–], 837 [921–C₅H₈O][–], 775 [921–146 C₆H₁₀O₄][–], 691 [775–C₅H₈O][–], 545 [691–C₆H₁₀O₄–C₅H₈O][–], 417, 271; HRFABMS m/z 1005.5630 [M–H][–] (calcd for C₅₀H₈₅O₂₀ requires 1005.5634).

4.4.5. Murucoidin XVI (5)

White powder; mp 125–127 °C; $[\alpha]_D -29^\circ$ (c 0.35, MeOH); ¹H and ¹³C NMR, see Tables 1 and 2; negative FABMS m/z 1005 [M–H][–], 921 [M–H–C₅H₈O][–], 691 [921–C₅H₈O–C₆H₁₀O₄][–], 545 [691–C₆H₁₀O₄][–], 417, 271; HRFABMS m/z 1005.5629 [M–H][–] (calcd for C₅₀H₈₅O₂₀ requires 1005.5634).

4.5. Alkaline hydrolysis of resin glycoside mixture

A solution of the crude resin glycoside mixture (100 mg) in 5% KOH–H₂O (5 ml) was heated at 95 °C for 4 h. The reaction mixture was acidified to pH 4.0 and extracted with CHCl₃ (30 ml). The organic layer was washed with H₂O, dried over anhydrous Na₂SO₄, and evaporated under reduced pressure. The aqueous phase was extracted with *n*-BuOH (20 ml) and concentrated to dryness. The

residue extracted (42 mg) from the aqueous phase was methylated with CH₂N₂ to further perform the separation by HPLC of the methyl ester derivatives, using a Waters μ Bondapak NH₂ column (7.8 \times 300 mm), an isocratic elution with CH₃CN–H₂O (5:1), a flow rate of 3 ml/min, and a sample injection of 500 μ l (20 mg/ml). This procedure yielded operculinic acid C methyl ester (6.4 mg, t_R = 5.8 min), operculinic acid E methyl ester (8.6 mg, t_R = 10.9 min), simonic acid A methyl ester (4.3 mg, t_R = 14.0 min), operculinic acid A methyl ester (8.6 mg, t_R = 20.9 min), and simonic acid B methyl ester (14.7 mg, t_R = 28.2 min), which were identified by comparison of their physical constants and NMR data with published value (Ono et al., 1989, 1990).

The residue from the organic phase was analyzed by GC–MS to allow the detection of the major liberated esterifying residues which were identified as 2-methyl propanoic, 2-methyl butanoic, and *n*-dodecanoic acids by comparison of their retention times and spectra with those of authentic samples as previously described (Bah et al., 2007; Chérigo et al., 2008). Previously described procedures were used for the preparation and identification of 4-bromophenacyl (2*S*)-2-methylbutyrate from the resin glycoside mixture: mp 40–42 °C; $[\alpha]_D +18$ (c 1.0, MeOH) (Pereda-Miranda and Hernández-Carlos, 2002).

4.6. Biological assays

4.6.1. Bacterial strains and media

Staphylococcus aureus EMRSA-15 containing the *mecA* gene was provided by Dr. Paul Stapleton, The School of Pharmacy, University of London. Strain XU-212, a methicillin-resistant strain possessing the TetK tetracycline efflux protein, was provided by Dr. E. Udo (Gibbons and Udo, 2000). SA-1199B, which over-expresses the NorA MDR efflux protein (Kaatz et al., 1993), and *S. aureus* ATCC 25923 were also used. All strains were cultured on nutrient agar (Oxoid, Basingstoke, UK) before determination of MIC values. Cation-adjusted Mueller–Hinton broth (MHB; Oxoid) containing 20 and 10 mg/l of Ca²⁺ and Mg²⁺, respectively was used for susceptibility tests.

4.6.2. Susceptibility testing

Minimum inhibitory concentration values (MIC) were determined at least in duplicate by standard microdilution procedures. An inoculum density of 5×10^5 cfu of each of the test strains was prepared in 0.9% saline by comparison with a McFarland standard. MHB (125 μ l) was dispensed into 10 wells of a 96-well microtiter plate (Nunc, 0.3 ml volume per well). All test compounds were dissolved in DMSO before dilution into MHB for use in MIC determinations. The highest concentration of DMSO remaining after dilution (3.125% v/v) caused no inhibition of bacterial growth. Then, glycolipids **1–5** or appropriate antibiotic (125 μ l) were dispensed into well 1 and serially diluted across the plate (512–1 μ g/ml), leaving well 11 empty for the growth control. The final volume was dispensed into well 12, which being free of inoculum served as the sterile control. The inoculum (125 μ l) was added into wells 1–11 and the plate was incubated at 36 °C for 18 h. The MIC was defined as the lowest concentration which yielded no visible growth. Tetracycline and norfloxacin from Sigma (Poole, UK) were also tested as positive drug controls. A methanolic solution (5 mg/ml) of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; Lancaster) was used to detect bacterial growth by a color change from yellow to dark blue. For the modulation assay, the murucoidins were tested at final concentrations of 25 or 5 μ g/ml. Serial doubling dilutions of norfloxacin ranging from 1 to 512 μ g/ml were added and the microtitre plates were then interpreted, after inoculum addition and incubation, in the same manner as MIC determinations. The activity of reserpine at a con-

centration of 20 µg/ml was also tested as an efflux pump inhibitor for comparison purposes. All samples were tested in duplicate.

4.6.3. Cytotoxicity assay

Nasopharyngeal (KB), cervix (HeLa), and laryngeal carcinoma (Hep-2) cell lines were maintained in RMPI 1640 (10×) medium supplemented with 10% fetal bovine serum. Cell lines were cultured at 37 °C in an atmosphere of 5% CO₂ in air (100% humidity). The cells at log phase of their growth cycle were treated in triplicate with various concentrations of the test samples (0.16–20 µg/ml) and incubated for 72 h at 37 °C in a humidified atmosphere of 5% CO₂. The cell concentration was determined by the NCI sulforhodamine method (Skehan et al., 1990). Results were expressed as the dose that inhibits 50% control growth after the incubation period (EC₅₀). The values were estimated from a semilog plot of the drug concentration (µg/ml) against the percentage of viable cells. Vinblastine was included as a positive drug control.

Acknowledgements

This research was partially supported by Consejo Nacional de Ciencia y Tecnología (45861-Q) and Dirección General de Asuntos del Personal Académico, UNAM (IN208307). R.P.-M. was on sabbatical leave at the Centre for Pharmacognosy and Phytotherapy (The School of Pharmacy, UL) with the final support of DGAPA (UNAM). L.C. is grateful to DGAPA for a graduate scholarship. Thanks are due to G. Duarte and M. Guzmán (USAI, Facultad de Química, UNAM) for the recording of mass spectra and to Dr. Mabel Fragoso-Serrano (Facultad de Química, UNAM) for HPLC technical assistance.

References

- Bah, M., Chérigo, L., Taketa, A.T.C., Fragoso-Serrano, M., Hammond, G.B., Pereda-Miranda, R., 2007. Intrapilosins I–VII, pentasaccharides from the seeds of *Ipomoea intrapilosa*. J. Nat. Prod. 70, 1153–1157.
- Bah, M., Pereda-Miranda, R., 1996. Detailed FAB-Mass spectrometry and high resolution NMR investigations of tricolorins A–E, individual oligosaccharides from the resins of *Ipomoea tricolor* (Convolvulaceae). Tetrahedron 52, 13063–13080.
- Chérigo, L., Pereda-Miranda, R., 2006. Resin glycosides from the flowers of *Ipomoea murucoides*. J. Nat. Prod. 69, 595–599.
- Chérigo, L., Pereda-Miranda, R., Fragoso-Serrano, M., Jacobo-Herrera, N., Kaatz, G.W., Gibbons, S., 2008. Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of *Ipomoea murucoides*. J. Nat. Prod. 71, 1037–1045.
- Duus, J.O., Gotfredsen, C.H., Bock, K., 2000. Carbohydrate structural determination by NMR spectroscopy: modern methods and limitations. Chem. Rev. 100, 4589–5614.
- Emmatt, E.W., 1940. The Badianus Manuscript (Codex Barberini, Latin 241). An Aztec Herbal of 1552. The Johns Hopkins Press, Baltimore.
- Gibbons, S., Oluwatuyi, M., Veitch, N.C., Gray, A.I., 2003. Bacterial resistance modifying agents from *Lycopus europaeus*. Phytochemistry 62, 83–87.
- Gibbons, S., Udo, E.E., 2000. The effect of reserpine, a modulator of multidrug efflux pumps, on the in-vitro activity of tetracycline against clinical isolates of methicillin resistant *Staphylococcus aureus* (MRSA) possessing the tet(K) determinant. Phytother. Res. 14, 139–140.
- Kaatz, G.W., Seo, S.M., Ruble, C.A., 1993. Efflux-mediated fluoroquinolone resistance in *Staphylococcus aureus*. Antimicrob. Agents Chemother. 37, 1086–1094.
- Oluwatuyi, M., Kaatz, G.W., Gibbons, S., 2004. Antibacterial and resistance modifying activity of *Rosmarinus officinalis*. Phytochemistry 65, 3249–3254.
- Ono, M., Kawasaki, T., Miyahara, K., 1989. Resin glycosides V. Identification and characterization of the component organic and glycosidic acids of the ether-soluble crude resin glycosides ("jalapin") from Rhizoma Jalapae Braziliensis (roots of *Ipomoea operculata*). Chem. Pharm. Bull. 37, 3209–3213.
- Ono, M., Fukunaga, T., Kawasaki, T., Miyahara, K., 1990. Resin glycosides VIII. Four glycosidic acids, operculinic acids D, E, F, and G of the ether-soluble crude resin glycosides ("jalapin") from rhizoma jalapae braziliensis (roots of *Ipomoea operculata*). Chem. Pharm. Bull. 38, 2650–2655.
- Pereda-Miranda, R., Bah, M., 2003. Biodynamic constituents in the Mexican morning glories: purgative remedies transcending boundaries. Curr. Top. Med. Chem. 3, 111–131.
- Pereda-Miranda, R., Escalante-Sánchez, E., Escobedo-Martínez, C., 2005. Characterization of lipophilic pentasaccharides from beach morning glory (*Ipomoea pes-caprae*). J. Nat. Prod. 68, 226–230.
- Pereda-Miranda, R., Hernández-Carlos, B., 2002. HPLC isolation and structural elucidation of diastereomeric niloyl ester tetrasaccharides from Mexican scammony root. Tetrahedron 58, 3145–3154.
- Pereda-Miranda, R., Kaatz, G.W., Gibbons, S., 2006. Polyacylated oligosaccharides from medicinal Mexican morning glory species as antibacterial and inhibitors of multidrug resistance in *Staphylococcus aureus*. J. Nat. Prod. 69, 406–409.
- Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Bokesch, H., Kenney, S., Boyd, M.R., 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107–1112.